Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 
Diseases » Leukemia » Stats
 

Statistics about Leukemia

Type statistics for Leukemia:

The following are statistics from various sources about the types of Leukemia:

Prevalence and incidence statistics for Leukemia:

See also prevalence and incidence page for Leukemia

Incidence (annual) of Leukemia: 30,800 annual cases in USA (SEER 2002 estimate) including 10,800 lymphocytic, 15,000 myeloid and 5,000 other leukemias; about 29,000 cases annually (NCI); nearly 27,000 adults and more than 2,000 children annually.

Incidence Rate: approx 1 in 8,831 or 0.01% or 30,800 people in USA [about data]

Incidence extrapolations for USA for Leukemia: 30,799 per year, 2,566 per month, 592 per week, 84 per day, 3 per hour, 0 per minute, 0 per second. Note: this extrapolation calculation uses the incidence statistic: 30,800 annual cases in USA (SEER 2002 estimate) including 10,800 lymphocytic, 15,000 myeloid and 5,000 other leukemias; about 29,000 cases annually (NCI); nearly 27,000 adults and more than 2,000 children annually.

Incidence of Leukemia: Each year, nearly 27,000 adults and more than 2,000 children in the United States learn that they have leukemia . (Source: excerpt from What You Need To Know About Leukemia: NCI)

Incidence statistics about Leukemia:

The following statistics relate to the incidence of Leukemia:

  • 33,440 new cases for leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 19,020 new male cases for leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 14,420 new female cases for leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 2,300 new cases of leukemia in men in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
  • 1,600 new cases of leukemia in women in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
  • 14 per 100,000 new cases of leukemia in men in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
  • 8 per 100,000 new cases of leukemia in women in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
  • 3,830 new cases for Acute Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 2,110 new male cases for Acute Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 1,720 new female cases for Acute Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 8,190 new cases for Chronic Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 5,050 new male cases for Chronic Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 3,130 new female cases for Chronic Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 11,920 new cases for Acute Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 6,280 new male cases for Acute Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 5,640 new female cases for Acute Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 4,600 new cases for Chronic Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 2,700 new male cases for Chronic Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 1,900 new female cases for Chronic Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 106,700 estimated cases in the USA 2004 for leukemia/lymphoma/myeloma (The Leukemia and Lymphoma Society Web Site, 2004)
  • Leukemia/lymphoma/myeloma accounts for 8.7% of all cancer cases diagnosed each year in the USA (The Leukemia and Lymphoma Society Web Site, 2004)
  • New case diagnosed every 5 minutes in the USA for leukemia/lymphoma/myeloma (The Leukemia and Lymphoma Society Web Site, 2004)
  • 300 new cases diagnosed each day in the USA for leukemia/lymphoma/myeloma (The Leukemia and Lymphoma Society Web Site, 2004)
  • more about incidence...»

Death and mortality statistics for Leukemia:

Deaths from Leukemia: 21,014 deaths reported in USA 1999 (NVSR Sep 2001)

Death rate extrapolations for USA for Leukemia: 21,013 per year, 1,751 per month, 404 per week, 57 per day, 2 per hour, 0 per minute, 0 per second. Note: this extrapolation calculation uses the deaths statistic: 21,014 deaths reported in USA 1999 (NVSR Sep 2001)

Death statistics for Leukemia:

The following are statistics from various sources about deaths and Leukemia:

  • 23,300 estimated deaths for leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 12,900 estimated male deaths for leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 10,310 estimated female deaths for leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 1,300 deaths in men from leukemia in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
  • 990 deaths in women from leukemia in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
  • 8 per 100,000 deaths in men from leukemia in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
  • 4 per 100,000 deaths in women from leukemia in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
  • 1,450 estimated deaths for Acute Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 820 estimated male deaths for Acute Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 630 estimated female deaths for Acute Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 4,800 estimated deaths for Chronic Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 2,730 estimated male deaths for Chronic Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 2,070 estimated female deaths for Chronic Lymphocytic Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 8,870 estimated deaths for Acute Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 4,810 estimated male deaths for Acute Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 4,060 estimated female deaths for Acute Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 1,570 estimated deaths for Chronic Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 940 estimated male deaths for Chronic Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 630 estimated female deaths for Chronic Myeloid Leukemia in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
  • Mortality rates for leukemia deaths in various countries:
    • 6.6 men per 100,000 population in the US 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.2 women per 100,000 population in the US 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.7 men per 100,000 population in Australia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.8 women per 100,000 population in Australia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.0 men per 100,000 population in Austria 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.6 women per 100,000 population in Austria 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.0 men per 100,000 population in Azerbaijan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 2.7 women per 100,000 population in Azerbaijan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.2 men per 100,000 population in Bulgaria 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.3 women per 100,000 population in Bulgaria 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 6.2 men per 100,000 population in Canada 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.9 women per 100,000 population in Canada 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.0 men per 100,000 population in Chile 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.0 women per 100,000 population in Chile 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 2.8 men per 100,000 population in China 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 2.0 women per 100,000 population in China 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.7 men per 100,000 population in Colombia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.9 women per 100,000 population in Colombia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.8 men per 100,000 population in Croatia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.5 women per 100,000 population in Croatia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.8 men per 100,000 population in Cuba 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.6 women per 100,000 population in Cuba 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 6.7 men per 100,000 population in Czech Republic 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.4 women per 100,000 population in Czech Republic 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.8 men per 100,000 population in Denmark 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.9 women per 100,000 population in Denmark 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.7 men per 100,000 population in Estonia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.9 women per 100,000 population in Estonia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.7 men per 100,000 population in Finland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.3 women per 100,000 population in Finland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 6.1 men per 100,000 population in France 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.9 women per 100,000 population in France 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.7 men per 100,000 population in Germany 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.9 women per 100,000 population in Germany 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 6.3 men per 100,000 population in Greece 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.8 men per 100,000 population in Greece 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 7.6 men per 100,000 population in Hungary 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.9 women per 100,000 population in Hungary 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.4 men per 100,000 population in Ireland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.3 women per 100,000 population in Ireland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 6.5 men per 100,000 population in Israel 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.5 women per 100,000 population in Israel 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.1 men per 100,000 population in Japan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 2.6 women per 100,000 population in Japan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.3 men per 100,000 population in Kazakhstan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 2.5 women per 100,000 population in Kazakhstan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.1 men per 100,000 population in Kyrgyzstan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.2 women per 100,000 population per 100,000 population in Kyrgyzstan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 6.0 men per 100,000 population in Latvia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000196.7 American Cancer Society)
    • 4.0 women per 100,000 population in Latvia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.7 men per 100,000 population in Lithuania 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.8 women per 100,000 population in Lithuania 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.3 men per 100,000 population in Macedonia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 2.7 women per 100,000 population in Macedonia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.4 men per 100,000 population in Mauritius 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 2.0 women per 100,000 population in Mauritius 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.9 men per 100,000 population in Mexico 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.0 women per 100,000 population in Mexico 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.0 men per 100,000 population in the Netherlands 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.2 women per 100,000 population in the Netherlands 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 6.3 men per 100,000 population in New Zealand 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.4 women per 100,000 population in New Zealand 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.6 men per 100,000 population in Norway 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.2 women per 100,000 population in Norway 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.6 men per 100,000 population in Poland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.5 women per 100,000 population in Poland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.1 men per 100,000 population in Portugal 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.4 women per 100,000 population in Portugal 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.2 men per 100,000 population in Republic of Moldova 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.3 women per 100,000 population in Republic of Moldova 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.5 men per 100,000 population in Romania 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.0 women per 100,000 population in Romania 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.0 men per 100,000 population in the Russian Federation 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.4 women per 100,000 population in the Russian Federation 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 7.1 men per 100,000 population in Slovakia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.7 women per 100,000 population in Slovakia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.9 men per 100,000 population in Slovenia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.2 women per 100,000 population in Slovenia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.4 men per 100,000 population in Spain 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.2 women per 100,000 population in Spain 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 5.1 men per 100,000 population in Sweden 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.3 women per 100,000 population in Sweden 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.4 men per 100,000 population in Trinidad and Tobago 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.1 women per 100,000 population in Trinidad and Tobago 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 2.6 men per 100,000 population in Turkmenistan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.4 women per 100,000 population in Turkmenistan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 4.9 men per 100,000 population in the UK 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.3 women per 100,000 population in the UK 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.9 men per 100,000 population in Venezuela 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
    • 3.2 women per 100,000 population in Venezuela 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.9% of all female deaths was due to leukaemia in Australia 2002 (AIHW National Morbidity Database, Australia’s Health 2004, AIHW)
  • 1.2% of all male deaths was due to leukaemia in Australia 2002 (AIHW National Morbidity Database, Australia’s Health 2004, AIHW)
  • 581 women died from leukaemia in Australia 2002 (AIHW National Morbidity Database, Australia’s Health 2004, AIHW)
  • 843 men died from leukaemia in Australia 2002 (AIHW National Morbidity Database, Australia’s Health 2004, AIHW)
  • Estimated 60,400 deaths in the USA 2004 for leukemia/lymphoma/myeloma (The Leukemia and Lymphoma Society Web Site, 2004)
  • 1 death occurs every 9 minutes in the USA for leukemia/lymphoma/myeloma (The Leukemia and Lymphoma Society Web Site, 2004)
  • Estimated 640,000 people in the USA with leukemia/lymphoma/myeloma (The Leukemia and Lymphoma Society Web Site, 2004)
  • 266 deaths for leukemia in New Zealand 1999 (New Zealand Health Information, 2002)
  • more about deaths...»

Survival rate statistics for Leukemia:

The following are statistics from various sources about the survival rate for Leukemia:

  • 48% of white people survive 5 years for leukemia in the US 1992-99 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 39% of African American people survive 5 years for leukemia in the US 1992-99 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 46% survive 5 years for leukemia in the US 1992-99 (Cancer Facts and Figures, American Cancer Society, 2004)
  • 38.3% of people with Leukemia survive after 5 years in the US 1983-90 (SEER)
  • 5-year survival rate for black people with leukaemia is 30.8% in the US 1983-90 (SEER)
  • 5-year survival rate for people with leukaemia is 38.3% in the US 1983-90 (SEER)
  • 5-year survival rate for white people with leukaemia is 39.5% in the US 1983-90 (SEER)
  • 5-year survival rate for white children under 15-years old with acute lymphocytic leukaemia is 75.0% in the US 1983-90 (SEER)
  • 5-year survival rate for white children under 15-years old with acute myeloid leukaemia is 29.4% in the US 1983-90 (SEER)
  • 1-year survival rate for men aged 15-99 with leukaemia is 57.4% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for men aged 15-99 with leukaemia is 32% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for men aged 15-39 with leukaemia is 75% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for men aged 15-39 with leukaemia is 47% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for men aged 40-49 with leukaemia is 76% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for men aged 40-49 with leukaemia is 51% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for men aged 50-59 with leukaemia is 72% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for men aged 50-59 with leukaemia is 47% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for men aged 60-69 with leukaemia is 64% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for men aged 60-69 with leukaemia is 36% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for men aged 70-79 with leukaemia is 52% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for men aged 70-79 with leukaemia is 26% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for men aged 80-99 with leukaemia is 38% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for men aged 80-99 with leukaemia is 17% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for women aged 15-99 with leukaemia is 55.5% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for women aged 15-99 with leukaemia is 33.6% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for women aged 15-39 with leukaemia is 74% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for women aged 15-39 with leukaemia is 49% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for women aged 40-49 with leukaemia is 69% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for women aged 40-49 with leukaemia is 42% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for women aged 50-59 with leukaemia is 69% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for women aged 50-59 with leukaemia is 45% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for women aged 60-69 with leukaemia is 62% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for women aged 60-69 with leukaemia is 41% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for women aged 70-79 with leukaemia is 51% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for women aged 70-79 with leukaemia is 28% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 1-year survival rate for women aged 80-99 with leukaemia is 38% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 5-year survival rate for women aged 80-99 with leukaemia is 19% in England and Wales 1991-95 (Cancer Survival, National Statistics)
  • 3 to 5 years is the life expectancy after diagnosis of chronic myelogenous leukemia if no treatment or transplant is done (MPD Research Centre, Association of Online Cancer Resources)
  • 20% of chronic myelogenous leukemia patients has a relapse during the first five years after a transplant (MPD Research Centre, Association of Online Cancer Resources)
  • 50% of chronic myelogenous leukemia patients will be in remission at 8 years if they receive a transplant within one year of being diagnosed as in the chronic phase (MPD Research Centre, Association of Online Cancer Resources)
  • more about deaths...»

Society statistics for Leukemia

Hospitalization statistics for Leukemia:

The following are statistics from various sources about hospitalizations and Leukemia:

  • 0.37% (46,787) of hospital consultant episodes were for lymphoid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 97% of hospital consultant episodes for lymphoid leukaemia required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 62% of hospital consultant episodes for lymphoid leukaemia were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 38% of hospital consultant episodes for lymphoid leukaemia were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 13% of hospital consultant episodes for lymphoid leukaemia required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 6.5 days was the mean length of stay in hospitals for lymphoid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 2 days was the median length of stay in hospitals for lymphoid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 37 was the mean age of patients hospitalised for lymphoid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 28% of hospital consultant episodes for lymphoid leukaemia occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 11% of hospital consultant episodes for lymphoid leukaemia occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 72% of hospital consultant episodes for lymphoid leukaemia were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 0.14% (73,019) of hospital bed days were for lymphoid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 0.29% (37,083) of hospital consultant episodes were for myeloid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 96% of hospital consultant episodes for myeloid leukaemia required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 56% of hospital consultant episodes for myeloid leukaemia were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 44% of hospital consultant episodes for myeloid leukaemia were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 13% of hospital consultant episodes for myeloid leukaemia required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 13 days was the mean length of stay in hospitals for myeloid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 6 days was the median length of stay in hospitals for myeloid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 55 was the mean age of patients hospitalised for myeloid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 50% of hospital consultant episodes for myeloid leukaemia occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 17% of hospital consultant episodes for myeloid leukaemia occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 68% of hospital consultant episodes for myeloid leukaemia were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 0.25% (128,372) of hospital bed days were for myeloid leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 0.002% (260) of hospital consultant episodes were for monocytic leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 88% of hospital consultant episodes for monocytic leukaemia required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 72% of hospital consultant episodes for monocytic leukaemia were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 28% of hospital consultant episodes for monocytic leukaemia were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 17% of hospital consultant episodes for monocytic leukaemia required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 13.6 days was the mean length of stay in hospitals for monocytic leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 8 days was the median length of stay in hospitals for monocytic leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 58 was the mean age of patients hospitalised for monocytic leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 31% of hospital consultant episodes for monocytic leukaemia occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 20% of hospital consultant episodes for monocytic leukaemia occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 58% of hospital consultant episodes for monocytic leukaemia were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 0.002% (1,037) of hospital bed days were for monocytic leukaemia in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 0.007% (868) of hospital consultant episodes were for leukaemia of unspecified cell type in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 90% of hospital consultant episodes for leukaemia of unspecified cell type required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 55% of hospital consultant episodes for leukaemia of unspecified cell type were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 45% of hospital consultant episodes for leukaemia of unspecified cell type were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 25% of hospital consultant episodes for leukaemia of unspecified cell type required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 12 days was the mean length of stay in hospitals for leukaemia of unspecified cell type in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 3 days was the median length of stay in hospitals for leukaemia of unspecified cell type in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 49 was the mean age of patients hospitalised for leukaemia of unspecified cell type in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 26% of hospital consultant episodes for leukaemia of unspecified cell type occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 26% of hospital consultant episodes for leukaemia of unspecified cell type occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 52% of hospital consultant episodes for leukaemia of unspecified cell type were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
  • 0.006% (3,015) of hospital bed days were for leukaemia of unspecified cell type in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)

About statistics:

This page presents a variety of statistics about Leukemia. The term 'prevalence' of Leukemia usually refers to the estimated population of people who are managing Leukemia at any given time. The term 'incidence' of Leukemia refers to the annual diagnosis rate, or the number of new cases of Leukemia diagnosed each year. Hence, these two statistics types can differ: a short-lived disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence. For more information see about prevalence and incidence statistics.

 

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise